Immunity With Acute Hepatits A (Hepatitis A)

April 17, 2025 updated by: Martina Adel Attia Massod, Assiut University

Assessment of Lymphocyte Subset Functions in Children Admitted to Assiut University Children Hospital With Acute Hepatitis A Infection

Hepatitis A Virus (HAV) is a public health concern in Egypt, especially among children. Historically highly endemic, recent studies suggest a changing epidemiology. While improved socioeconomic conditions have reduced its spread, HAV remains prevalent, with over 50% of Egyptians exposed by age 15. Infection is often asymptomatic or mild in children but can be more severe with age. Prevention relies on improved sanitation and hygiene, with vaccin and recov

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Introduction

Hepatitis A virus (HAV) infection remains a significant public health concern in Egypt, particularly among children. Egypt has historically been considered an area of high endemicity for HAV infection, with the highest prevalence occurring in early childhood. Recent studies, however, suggest a shifting epidemiological pattern. An estimated 8-10 million people suffer from viral hepatitis in Egypt, with HAV being one of the major causative agents.

The seroprevalence of HAV antibodies among Egyptian children has shown significant variability in recent years, reflecting changes in socioeconomic conditions and public health measures.

A study conducted in 2008 found that 61.4% of Egyptian children aged 2.5-18 years were seropositive for HAV antibodies. This study revealed a significant increase in HAV seroprevalence with higher age and lower social class. (WHO EMRO | Seroprevalence of Hepatitis A Virus, n.d.)Notably, among children under 6 years old, 72.7% from high social classes were seronegative for HAV antibodies, compared to only 19.0% from low social classes. These findings suggest that improvements in socioeconomic conditions may be altering the epidemiological landscape of HAV in Egypt.

More recent data indicate that HAV infection remains prevalent in Egypt, with 50% or more of the Egyptian population exposed to HAV by the age of 15. This high rate of early childhood exposure has important implications for public health strategies and vaccination policies.

Hepatitis A in children is often asymptomatic or presents with mild, non-specific symptoms. However, the severity of the disease tends to increase with age. In symptomatic cases, children may experience fever, fatigue, nausea, abdominal pain, and jaundice. While most cases resolve spontaneously without complications, severe manifestations such as fulminant hepatitis and liver failure have been reported in Egypt.

The risk of complications appears to be influenced by various factors, including age, nutritional status, and pre-existing liver conditions. In Egypt, where chronic liver diseases due to hepatitis B and C are prevalent, superinfection with HAV can lead to more severe outcomes.

Given the high prevalence of HAV in Egypt, prevention strategies are crucial. Improved sanitation and hygiene practices have contributed to reducing HAV transmission. However, vaccination remains the most effective preventive measure.

Currently, hepatitis A vaccination is not part of the standard immunization program in Egypt. The decision to implement universal vaccination should be based on cost-effectiveness analyses and the changing epidemiology of HAV in the country. Some experts recommend vaccination for high social class children at the preschool period without prior testing for HAV antibodies, while for middle social class children, vaccination after testing for HAV antibodies is suggested The immune response to HAV infection plays a crucial role in disease progression and resolution. In acute HAV infection, both innate and adaptive immune responses are activated. Natural Killer (NK) cells, part of the innate immune system, show a significant increase in the initial phase of acute hepatitis A, suggesting an important role in the first line of defense.

The adaptive immune response, particularly T cell-mediated immunity, is critical for viral clearance and long-term protection. Recent studies have highlighted the dominance of CD4+ T helper cell responses during acute resolving HAV infection.

CD4+ T cells produce multiple cytokines when viremia first declines and play a crucial role in the termination of HAV infection. In contrast, HAV-specific CD8+ T cells often fail to display effector functions until after viremia and hepatitis begin to subside.

Humoral immunity also plays a significant role in HAV infection. IgM anti-HAV antibodies appear within a few days of symptom onset and generally become undetectable within 4 months. Anti-HAV IgG antibodies, on the other hand, persist for life, providing long-term protection against reinfection.

Study Type

Observational

Enrollment (Estimated)

50

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Children aged 1-15 years

Description

Inclusion Criteria:

  • Children aged 1-15 years
  • Confirmed diagnosis of acute hepatitis A infection (positive anti-HAV IgM)
  • Admitted to the hospital for management of acute hepatitis A
  • Parental/guardian consent and child assent (where appropriate) obtained

Exclusion Criteria:

  • Known pre-existing liver disease or chronic hepatitis
  • Immunodeficiency disorders or current immunosuppressive therapy
  • Coinfection with other hepatotropic viruses (HBV, HCV, HEV)
  • Severe malnutrition
  • Recent blood transfusion (within 3 months)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Correlation between lymphocyte subset levels and development of hepatic encephalopathy or fulminant hepatic failure
Time Frame: One year
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2025

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

April 17, 2025

First Submitted That Met QC Criteria

April 17, 2025

First Posted (Actual)

April 24, 2025

Study Record Updates

Last Update Posted (Actual)

April 24, 2025

Last Update Submitted That Met QC Criteria

April 17, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Lymphocyte subset functions

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis A

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe